PRAX Quote, Financials, Valuation and Earnings

Precision BioSciences has a net margin of -17188.74% compared to Praxis Precision Medicines's net margin of -2851.56%. Praxis Precision Medicines's return on equity of -63.57% beat Precision BioSciences's return on equity of 19.19%.

Praxis Precision Medicines has a consensus price target of $162.60, signalling upside risk potential of 157.48%. On the other hand Precision BioSciences has an analysts' consensus of $33.60 which suggests that it could grow by 489.47%. Given that Precision BioSciences has higher upside potential than Praxis Precision Medicines, analysts believe Precision BioSciences is more attractive than Praxis Precision Medicines.

Praxis Precision Medicines has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Precision BioSciences has a beta of 1.514, suggesting its more volatile than the S&P 500 by 51.431%.

Praxis Precision Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precision BioSciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines pays -- of its earnings as a dividend. Precision BioSciences pays out -- of its earnings as a dividend.

Praxis Precision Medicines quarterly revenues are $302K, which are smaller than Precision BioSciences quarterly revenues of $576K. Praxis Precision Medicines's net income of -$51.9M is lower than Precision BioSciences's net income of -$16.4M. Notably, Praxis Precision Medicines's price-to-earnings ratio is -- while Precision BioSciences's PE ratio is 95.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines is 597.09x versus 0.44x for Precision BioSciences. Usually stocks with elevated PS ratios are considered overvalued.

Exelixis has a net margin of -17188.74% compared to Praxis Precision Medicines's net margin of 21.87%. Praxis Precision Medicines's return on equity of -63.57% beat Exelixis's return on equity of 20.97%.

Praxis Precision Medicines has a consensus price target of $162.60, signalling upside risk potential of 157.48%. On the other hand Exelixis has an analysts' consensus of $34.47 which suggests that it could fall by -4.3%. Given that Praxis Precision Medicines has higher upside potential than Exelixis, analysts believe Praxis Precision Medicines is more attractive than Exelixis.

Praxis Precision Medicines has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Exelixis has a beta of 0.534, suggesting its less volatile than the S&P 500 by 46.575%.

Praxis Precision Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exelixis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines pays -- of its earnings as a dividend. Exelixis pays out -- of its earnings as a dividend.

Praxis Precision Medicines quarterly revenues are $302K, which are smaller than Exelixis quarterly revenues of $539.5M. Praxis Precision Medicines's net income of -$51.9M is lower than Exelixis's net income of $118M. Notably, Praxis Precision Medicines's price-to-earnings ratio is -- while Exelixis's PE ratio is 23.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines is 597.09x versus 5.21x for Exelixis. Usually stocks with elevated PS ratios are considered overvalued.

Marinus Pharmaceuticals has a net margin of -17188.74% compared to Praxis Precision Medicines's net margin of -283.63%. Praxis Precision Medicines's return on equity of -63.57% beat Marinus Pharmaceuticals's return on equity of -1150.43%.

Praxis Precision Medicines has a consensus price target of $162.60, signalling upside risk potential of 157.48%. On the other hand Marinus Pharmaceuticals has an analysts' consensus of $1.07 which suggests that it could grow by 98.64%. Given that Praxis Precision Medicines has higher upside potential than Marinus Pharmaceuticals, analysts believe Praxis Precision Medicines is more attractive than Marinus Pharmaceuticals.

Praxis Precision Medicines has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Marinus Pharmaceuticals has a beta of 1.035, suggesting its more volatile than the S&P 500 by 3.471%.

Praxis Precision Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marinus Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines pays -- of its earnings as a dividend. Marinus Pharmaceuticals pays out -- of its earnings as a dividend.

Praxis Precision Medicines quarterly revenues are $302K, which are smaller than Marinus Pharmaceuticals quarterly revenues of $8.5M. Praxis Precision Medicines's net income of -$51.9M is lower than Marinus Pharmaceuticals's net income of -$24.2M. Notably, Praxis Precision Medicines's price-to-earnings ratio is -- while Marinus Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines is 597.09x versus 0.97x for Marinus Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Protagonist Therapeutics has a net margin of -17188.74% compared to Praxis Precision Medicines's net margin of -710.37%. Praxis Precision Medicines's return on equity of -63.57% beat Protagonist Therapeutics's return on equity of 37.59%.

Praxis Precision Medicines has a consensus price target of $162.60, signalling upside risk potential of 157.48%. On the other hand Protagonist Therapeutics has an analysts' consensus of -- which suggests that it could grow by 57.06%. Given that Praxis Precision Medicines has higher upside potential than Protagonist Therapeutics, analysts believe Praxis Precision Medicines is more attractive than Protagonist Therapeutics.

Praxis Precision Medicines has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Protagonist Therapeutics has a beta of 2.232, suggesting its more volatile than the S&P 500 by 123.184%.

Praxis Precision Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protagonist Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines pays -- of its earnings as a dividend. Protagonist Therapeutics pays out -- of its earnings as a dividend.

Praxis Precision Medicines quarterly revenues are $302K, which are smaller than Protagonist Therapeutics quarterly revenues of $4.7M. Praxis Precision Medicines's net income of -$51.9M is lower than Protagonist Therapeutics's net income of -$33.2M. Notably, Praxis Precision Medicines's price-to-earnings ratio is -- while Protagonist Therapeutics's PE ratio is 13.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines is 597.09x versus 6.98x for Protagonist Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.